Parkinson’s: gold nanoparticles show preliminary signals in rodents

Could gold nanoparticles become a potential treatment for Parkinson’s disease? A systematic review reports improvements in some motor tests in rodents. But this exploratory review brings together small, heterogeneous studies: it demonstrates no benefit in people with Parkinson’s.

Conceptual illustration of gold nanoparticles being studied in animal models of Parkinson’s disease.
Gadgets & TechEditorial illustration, not study data.

Ten animal studies, not a trial in patients

The researchers selected ten studies involving mammalian models of Parkinson’s, in this case rodents, treated with different gold nanoparticle formulations. Their literature search was conducted in PubMed, Embase and Scopus on October 10, 2024.

They conducted three exploratory meta-analyses: general locomotor activity, motor coordination and dopaminergic system integrity. Oxidative stress markers were described separately. The available abstract does not specify the total number of animals, the duration of the interventions or the comparators used in each experiment.

Positive motor outcomes, but limited precision

For the rotarod, a motor coordination test, the pooled standardized effect is 2.33, with a 95% confidence interval ranging from 0.04 to 4.62. This result is based on four comparisons. The very wide interval leaves substantial uncertainty about the true size of the effect.

Locomotor activity measured in the open-field test also shows a favorable result, based on three comparisons. These measures describe animal behavior in experimental tests. They cannot quantify any improvement in symptoms or independence in patients.

The dopaminergic signal remains uncertain

The pooled estimate for dopaminergic system integrity is positive, but its confidence interval includes zero. It therefore remains compatible with no effect. Oxidative stress markers point in a favorable direction, but were not included in a pooled quantitative estimate.

These observations offer biological leads for further investigation. They prove neither neuronal protection in humans nor a slowing of Parkinson’s disease.

A research avenue, not an established treatment option

Small samples, differences between animal models and formulations, and a largely unclear risk of bias weaken the overall evidence. The authors call for standardized protocols and larger confirmatory preclinical studies.

The abstract reviewed also does not allow the safety of these formulations to be assessed. These results therefore do not justify personal use of gold nanoparticles for Parkinson’s.

Limitations to keep in mind

Only the PubMed abstract was reviewed, not the full text. The data are exclusively from animals, the formulations are heterogeneous and the estimates are imprecise. The authors declare that they received no funding. Conflicts of interest are not reported in the excerpt provided.

What we can take away

This review identifies motor signals in rodents that are interesting enough to warrant further research, but insufficient to establish a therapeutic benefit in humans.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.